ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2015
MicroRNA-15a down-regulation is associated with adverse prognosis in human glioma.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 12 citations in OpenAlex.
- Prognostic Value of MicroRNA-15a in Human Cancers: A Meta-Analysis and Bioinformatics.BioMed research international · 2019Pooled it
- Pooled it
- Exploring the Role of microRNAs in Glioma Progression, Prognosis, and Therapeutic Strategies.Cancers · 2023Review
- Plasma microRNA-720 may predict prognosis and diagnosis in glioma patients.Bioscience reports · 2020Observational
- MicroRNA-15a tissue expression is a prognostic marker for survival in patients with clear cell renal cell carcinoma.Clinical and experimental medicine · 2019Article
- Expression of microRNAs in tumors of the central nervous system in pediatric patients in México.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2017Article
- Knockdown of Long Noncoding RNA CCAT2 Inhibits Cellular Proliferation, Invasion, and Epithelial-Mesenchymal Transition in Glioma Cells.Oncology research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate whether miR-15a has prognostic relevance in human gliomas.
methodsThe expression levels of miR-15a were analyzed in glioma surgical resection tissues by microarray and quantitative real-time PCR. Survival analysis by the Kaplan-Meier method was performed to assess prognostic significance.
resultsDownregulation of miR-15a was detected in most primary gliomas, which was confirmed by qRT-PCR analysis. Additionally, the down-regulation of miR-15a was significantly associated with the WHO grade (P = 0.003), the low KPS (P = 0.027), time to recurrence (P = 0.044) and the poor OS (P = 0.046). Using Kaplan-Meier analysis, a comparison of survival curves of low versus high expresser of miR-15a revealed a highly significant difference in OS (P = 0.001) and DFS (P = 0.006), which suggested that low expression of miR-15a is associated with a worse prognosis. Multivariate analyses showed that miR-15a expression was independent risk factors predicting OS [Hazard ratio (HR), 7.52; 95 % confidence interval (CI), 2.63-21.47; P = 0.002] and DFS [HR, 11.56; 95 % CI, 5.17-25.96; P < 0.001] in glioma.
conclusionsThese findings indicated for the first time that the expression of miR-15a is significantly correlated with prognosis in glioma patients, suggesting that the miR-15a may serve as independent prognostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.